Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide-Reference-Cited by-同舟云学术

Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide

Published:2019-09 Issue: Volume:17 Page:601-614
ISSN:2162-2531
Container-title:Molecular Therapy - Nucleic Acids
language:en
Short-container-title:Molecular Therapy - Nucleic Acids

Author:

Kourkouta Eleni,Weij Rudie,González-Barriga Anchel,Mulder Melissa,Verheul Ruurd,Bosgra Sieto,Groenendaal Bas,Puoliväli Jukka,Toivanen Jussi,van Deutekom Judith C.T.,Datson Nicole A.

Funder

BioMarin

Publisher

Elsevier BV

Subject

Drug Discovery,Molecular Medicine

Reference49 articles.

1. Hereditary Ataxia Overview;Bird,1993

2. Polyglutamine spinocerebellar ataxias—from genes to potential treatments;Paulson;Nat. Rev. Neurosci.,2017

3. Survival and severity in dominant cerebellar ataxias;Monin;Ann. Clin. Transl. Neurol.,2015

4. High relative frequency of SCA1 in Poland reflecting a potential founder effect;Krysa;Neurol. Sci.,2016

5. Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis;van de Warrenburg;Neurology,2002

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3;Disease Models & Mechanisms;2023-09-01

2. Arzneimitteltherapie von Ataxien;DGNeurologie;2023-06-08

3. Therapeutic Strategies for Spinocerebellar Ataxia Type 1;Biomolecules;2023-05-02

4. The potential value of disease-modifying therapy in patients with spinocerebellar ataxia type 1: an early health economic modeling study;Journal of Neurology;2023-04-19

5. Blood neurofilament light chain levels are associated with disease progression in a transgenic SCA3 mouse model;2023-03-01